A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 To 15 Months of Age Receiving a Single Booster Dose
Latest Information Update: 17 Feb 2026
At a glance
- Drugs GSK 5459248 (Primary) ; PCV 20
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 17 Feb 2026 New trial record